Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triangle Coviracil NDA Slated For September; Abbott Bows Out As Partner

Executive Summary

Triangle Pharmaceuticals will file an NDA for Coviracil in September without a marketing partner following the reacquisition of rights to the nucleoside reverse transcriptase inhibitor from Abbott

You may also be interested in...



Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life

Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy

Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life

Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy

Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005

Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals

Related Content

UsernamePublicRestriction

Register

PS040319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel